****

**OBN Awards Entry Form: Deadline for first round entries is Friday 14 August 2020**

**(NB: The OBN Awards are open to all UK and European Registered companies.)**

|  |  |
| --- | --- |
| Name of Applicant:  JACKELINE PALMA | Job Title: Founder - Director |
| Company Name: CIRCAGENE Ltd | Company Address:  7 Bell Yard London  WC2A2JR  |
| Email Address:  jacky@circagene.com | Telephone Number: 0790-343-7506 |
| Name of Company Nominated (if different from the above):   | Nominee Contact: Francois PaillierJackeline Palma |
| Award Category you would like to enter (see below this form page):   BIOSEED ONE TO WATCH |
| Please submit your first-round entry here in response to criteria on previous page, please do not exceed 750 words. NB: When completing this form, please ensure you respond to each point of the category criteria in turn. CircaGene is a disruptive and innovative company revolutionising and pioneers in the Genetic Testing Market with personalised reports combined with our Patented Encryption Technology for the first solution to the DNA Privacy problem not only for consumer but also for the Life Sciences industry. We are the First World’s Incognito Test that guarantees owners privacy. We have customers in 7 countries; and we are profitable since day 1.CircaGene’s business model plan goes B2C, B2B, B2G.* (B2C) Saliva collection kits for personalised genetic testing
* (B2B & B2G) Encryption Licensing for Business in Life Sciences from Medical Records, Electronic Implants, DNA applications and much more.
* (B2B2C) We also do customised Bioinformatics/Genomics Analysis that guarantees constant income; collaborating with corporations like United Nations for R&D projects saving children in Africa.

Our plan is to become a standard to Encrypt and Manipulate Life Sciences sensible data like medical records, imaging, drug trials, clinical trials, research and development using molecular applications. Guaranteed privacy to the DNA individuals either for personal information or further in research and records. Our Patented encryption is the future of DNA manipulation and the most sensible data we can own. Our Optimized Fully Homomorphic Encryption (oFHE) is the imminent technological solution. We are scalable, optimized and potential is literally unlimited Life Science Applications. Our oFHE applications are above BlockChain, as you do not need to decrypt the data to use like in other encryption technologies. We applied all this knowledge to science to DNA and molecular application with the vision of the most and ultimate level of privacy. Our mission is to provide world-class Genetics; to protect and improve Public Health.You cant replace your DNA like a credit card, you can’t know where and how the corporations use your DNA data and then comes back at you in the future; when you ask for a job, when your kids ask a mortgage and gets denied “based on a genetic predisposition”, this scenario is not fiction. More than 100 million DNA records had been compromised in the world. Companies like 23&me selling data without consent to GSK and big pharma’s. AncestryDNA decrypting the DNA and selling it to the FBI, legislation in DNA is poor and without boundaries the damage is irreparable.In addition to the lack f privacy, competitors are daring to give information based on 1% of the DNA data available in each individual. CircaGene is the difference, as scientist we are committed to give accurate information; our Principal Scientist is the patent inventor of sequencing method for Oxford Nanopore, our Principal Bioinformatician has develop assays for space safety, with the talented team behind CircaGene we are dedicated to precision.The GLOBAL TAM is valued at approximately $824.1 million in 2018 and is anticipated to reach $Bn 30+ million by 2028 (May 28, 2020 06:30 ET | Source: Research and Markets). CircaGene is the first company to address these issues of accuracy and privacy in one added value. Making CircaGene a BioSeed one to Watch. With a huge potential, huge revenues and huge impact to come – just think, would you like to protect yourself and your beloved ones? Know your health risks and secure your future? CircaGene successfully raised so far £212,500 GBP on PRE-SEED ROUND.            |

Once complete, please submit this form by email to [events@obn.org.uk](file://obn-sbs/public/OBN/EVENTS/Events/2018/10.%20October/OBN%20Awards%202018/Award%20Categories/events%40obn.org.uk)

For queries, please email: jane.odriscoll@obn.org.uk or or call OBN on 0845 5215 222

**Many thanks for your entry and good luck!**

**OBN Awards 2020 - Categories and Criteria**

|  |  |
| --- | --- |
| **Award Category**  | **Entry Criteria**  |
| Best Start-up Biotech Company   | Recognises a UK or European registered start-up biotech company that best meets the following criteria: * Incorporated on or after 1 June 2018
* Proof of successful seed or Series A fundraising or grant success
* Early clinical trial activity or proof of concept
* Early assembly of experienced and credible management team and board
* Clear evidence of early stage implementation of a robust business plan
* Evidence of news flow

  |
| Best Emerging Biotech Company  | Recognises a UK or European registered emerging biotech company that best meets the following criteria: * Incorporated on or after 1 June 2015 but before 1 June 2018
* Evidence of a credible product pipeline or proof of concept
* Proof of significant clinical trial activity
* Proof of continued fundraising
* Evidence of a strong team in place – Management and Board
* Proof of developing partnerships and collaborations
* Clear evidence of a robust business plan to support continued growth
* Evidence of news flow
* Well organised, updated and informative website
 |
| Best Established Biotech Company   | Recognises a UK or European registered established biotech company that best meets the following criteria: * Incorporated before 1 June 2015
* Strong progress in clinical trials or product development
* Proof of ongoing fundraising or revenues
* Evidence of business success and deals
* Evidence of a strong team in place
* Proof of established partnerships and collaborations
* Evidence of news flow
 |
| Best Start-up Medtech Company  | Recognises a UK or European registered start-up medtech company that best meets the following criteria: * Incorporated on or after 1 June 2018
* Proof of successful seed or Series A fundraising
* A summary outline of the novel technology or approach, including why it is different and how/why it will be impactful
* Clear evidence of early stage implementation of a robust business plan
* Evidence of news flow

  |
| Best Emerging Medtech Company | Recognises a UK or European registered emerging medtech company that best meets the following criteria: * Incorporated in the UK on or after 1 June 2015 but before 1 June 2018
* A summary outline of the the novel technology or approach, including why it is different and how it is starting to positively impact patients
* Proof of continued fundraising or revenue
* Evidence of a strong team in place – Management and Board
* Proof of developing partnerships and collaborations
* Clear evidence of a robust business plan to support continued growth
* Evidence of clinical trial activity
* Evidence of news flow
* Well organised, updated and informative website
 |
| Best Established Medtech Company  | Recognises a UK or European registered established medtech company that best meets the following criteria: * Incorporated before 1 June 2015
* A summary outline of the technology or approach, including why it is different and how it is going to or is making a significant impact on patients
* Proof of ongoing fundraising or revenue generation
* Clinical trial activity and success
* Evidence of sales and marketing activity success
* Proof of developing partnerships and collaborations
* Clear evidence of a robust business plan to support continued growth
* Evidence of a strong team in place
* Evidence of news flow
 |
| Most Transformative Digital Healthcare Company  | Recognises a UK or European registered company using a digital technology to improve patient outcomes, and best meets the following criteria: * Shows clear evidence of how the technology is improving patient outcomes in either a clinical setting or via self-management
* Evidence of uptake by patients or healthcare providers in the UK or abroad
* Clear evidence of a robust business plan to support continued growth
* Evidence of significant news flow
* Website functionality
 |
| Best CRO    | This award is intended to recognise outstanding performance by a CRO offering either specialist or broad ranging services. Please provide the following information to support your entry:* An overview of the services you provide including differentiators between you and others in the industry
* Examples of companies that you have supported from conception to market approval, that showcase your service value
* Sample client testimonials and endorsements
* Evidence of strategic impact for the client
 |
| Best Business Support Organisation  | This is a broad ranging award that recognises outstanding levels of support or service to companies in the life sciences sector. The winner could be a data management company, law firm, IP agent, science park, sector organisation or government body.  Applicants are asked to submit a summary that outlines the outstanding support they provide to the industry and why they are unique.Please include case studies from clients/customers highlighting how the support has positively impacted their business/es. |
| The BioSeed® ‘One to Watch’ Award  | This award recognises an organisation or individual that has recently received grant funding or seed stage funding and presented at the OBN BioSeed pitching event in January 2020.  The judges will consider the broad progress that each entrant has made since November, in line with their business strategy.  |
| Most Impactful UK Deal  | This award recognises either a noteworthy investment, high value deal, collaboration or acquisition completed in the UK throughout 2019, that has had a positive impact on the life sciences industry. Please provide a summary outlining:* The details of the deal, collaboration or acquisition
* How the deal has had an impact on the life sciences industry
* Whether it has instigated a step-change for similar deals in a particular sector
* What have been the positive outcomes from the deal? E.g. progression of research, positive outcome for patients?
 |
| Special Recognition Award  | This award celebrates a pioneering individual whose continued support throughout the life sciences industry has enabled the growth and development of many start-up and emerging companies.  |